Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Methods in Neuroepidemiology

Free Access

Methodology of the Global and Regional Burden of Stroke Study

Author affiliations

aNational Institute for Stroke and Applied Neuroscience, School of Rehabilitation and Occupation Studies, Auckland University of Technology, bDepartment of Psychology, Faculty of Science, cSchool of Population Health, and dDepartment of Medicine, University of Auckland, Auckland, and eSchool of Psychology, Faculty of Arts and Social Sciences, University of Waikato, Hamilton, New Zealand

Corresponding Author

Derrick A. Bennett

Clinical Trials Service Unit, Richard Doll Building, Old Road Campus

Roosevelt Drive

Oxford OX3 7LF (UK)

Tel. +44 1865 743949, E-Mail derrick.bennett@ctsu.ox.ac.uk

Related Articles for ""

Neuroepidemiology 2012;38:30–40

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Setting priorities for the prevention of stroke requires an empirical understanding of the pattern of disease burden and exposure to major risk factors. In this manuscript we aim to report the methodology of a systematic review of the epidemiological literature on stroke and how this information will be synthesized to produce updated estimates of the global burden of stroke. Methods: We will use multi-state models implemented in the software program DisMod III to estimate age-specific prevalence, incidence, and early case-fatality (defined as either 28-day, 30-day or 1-month case fatality) for stroke by the 21 global burden of disease (GBD) regions as well as by gender and pathological stroke type based on information obtained from a systematic review. We conducted a two-stage search strategy in order to identify studies published between 1980 and 2011 for the GBD stroke review. Eligible studies: (a) distinguished between stroke and transient ischaemic attack (TIA); (b) distinguished between 1st ever and recurrent stroke; (c) reported on age-specific rates; (d) if reported, provided survival status within 28 days, 30 days or 1 month of onset for fatal and non-fatal events; (e) specified methods for ascertaining stroke cases, and (f) described imaging modalities to determine stroke subtypes. Details of included studies were recorded on a detailed data extraction form by trained reviewers. We will gather information on demographics, natural history and clinical outcomes (e.g. Rankin scale, Glasgow Coma Scale), after stroke which will be used to facilitate the estimation of epidemiological parameters. Reporting and methodological quality was rated. Populations were coded as urban, rural, or combined and studies classified as national, sub-national, healthcare system-based, or community level. Studies published in non-English languages were translated and coded centrally. Discussion: In international health research, there is a crucial need for accurate assessment of global health patterns. A thorough GBD reassessment of stroke will ensure that global health policy decisions are based on the most up-to-date, valid and reliable epidemiological information available.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Methods in Neuroepidemiology

Received: February 16, 2011
Accepted: November 01, 2011
Published online: December 17, 2011
Issue release date: January 2012

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 4

ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)

For additional information: http://www.karger.com/NED

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.